文献速递血脂与心血管预防心力衰竭与心肌病冠心病

设计下一代肥胖药物心脏代谢结局试验

Designing Next-Generation Cardiometabolic Outcome Trials for Obesity Medicines.
PubMed 文献 · J Am Coll Cardiol · 2026-03-11

肥胖患病率已达大流行程度,增加2型糖尿病、高血压、慢性肾脏病及心血管疾病风险。早期通过饮食运动或早期药物治疗减重的随机临床试验未改善心血管结局,而近期使用GLP-1受体激动剂在肥胖个体中显示出心血管获益。目前多项新型GLP-1受体激动剂及靶向多激素通路的研究产品的心血管结局试验(CVOT)正在计划或进行中,但测试新型肥胖药物的CVOT最佳设计特征可能需要演变。本篇评论结合既往和正在进行的临床试验及靶向肥胖的CVOT的未来,讨论肥胖药物CVOT的监管方面和研究设计考虑,并提出5项原则以指导下一代心肾代谢结局试验。

要点

  • 肥胖增加2型糖尿病、高血压、慢性肾脏病及心血管疾病风险。
  • 近期GLP-1受体激动剂在肥胖个体中显示出心血管获益。
  • 提出5项原则指导下一代心肾代谢结局试验设计。

核心结论

  • 测试新型肥胖药物的CVOT最佳设计特征可能需要演变,并提出5项原则指导下一代心肾代谢结局试验。

研究设计与样本

  • 本篇为评论文章,结合既往和正在进行的临床试验及靶向肥胖的CVOT的未来进行讨论。

主要发现

  • 早期通过饮食运动或早期药物治疗减重的随机临床试验未改善心血管结局。
  • 近期使用GLP-1受体激动剂在肥胖个体中显示出心血管获益。
  • 目前多项新型GLP-1受体激动剂及靶向多激素通路的研究产品的CVOT正在计划或进行中。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The prevalence of obesity has reached pandemic proportions and is having enormous public health effects. Obesity increases the risk of type 2 diabetes, hypertension, chronic kidney disease, and cardiovascular (CV) disease including coronary artery disease, heart failure, atrial fibrillation, and stroke. Although initial randomized clinical trials of weight-loss strategies through diet and exercise or early medical therapies did not lead to improved CV outcomes, more recent trials using glucagon-like peptide-1 (GLP-1) receptor agonists in individuals with obesity have demonstrated CV benefits. At present, there are multiple cardiovascular outcome trials (CVOTs) of novel GLP-1 receptor agonists and investigational products targeting multiple hormonal pathways planned or underway. However, the optimal design features of CVOTs testing novel obesity medications may need to evolve. In this commentary, we discuss regulatory aspects and study design considerations of CVOTs for obesity medications in the context of previous and ongoing clinical trials and the future of CVOTs targeting obesity. We also propose 5 principles to help guide next-generation cardio-kidney-metabolic outcome trials.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Platz E, Peikert A, Bozkurt B, et al. Designing Next-Generation Cardiometabolic Outcome Trials for Obesity Medicines. J Am Coll Cardiol. 2026. PMID: 41811272. doi:10.1016/j.jacc.2026.01.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。